Cargando…
Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832687/ https://www.ncbi.nlm.nih.gov/pubmed/35148739 http://dx.doi.org/10.1186/s12890-022-01855-w |
_version_ | 1784648775319420928 |
---|---|
author | Straßburg, Svenja Linker, Carolin-Maria Brato, Sebastian Schöbel, Christoph Taube, Christian Götze, Jürgen Stehling, Florian Sutharsan, Sivagurunathan Welsner, Matthias Weinreich, Gerhard |
author_facet | Straßburg, Svenja Linker, Carolin-Maria Brato, Sebastian Schöbel, Christoph Taube, Christian Götze, Jürgen Stehling, Florian Sutharsan, Sivagurunathan Welsner, Matthias Weinreich, Gerhard |
author_sort | Straßburg, Svenja |
collection | PubMed |
description | BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF. |
format | Online Article Text |
id | pubmed-8832687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88326872022-02-11 Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system Straßburg, Svenja Linker, Carolin-Maria Brato, Sebastian Schöbel, Christoph Taube, Christian Götze, Jürgen Stehling, Florian Sutharsan, Sivagurunathan Welsner, Matthias Weinreich, Gerhard BMC Pulm Med Research BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF. BioMed Central 2022-02-11 /pmc/articles/PMC8832687/ /pubmed/35148739 http://dx.doi.org/10.1186/s12890-022-01855-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Straßburg, Svenja Linker, Carolin-Maria Brato, Sebastian Schöbel, Christoph Taube, Christian Götze, Jürgen Stehling, Florian Sutharsan, Sivagurunathan Welsner, Matthias Weinreich, Gerhard Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title | Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title_full | Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title_fullStr | Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title_full_unstemmed | Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title_short | Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
title_sort | investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832687/ https://www.ncbi.nlm.nih.gov/pubmed/35148739 http://dx.doi.org/10.1186/s12890-022-01855-w |
work_keys_str_mv | AT straßburgsvenja investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT linkercarolinmaria investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT bratosebastian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT schobelchristoph investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT taubechristian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT gotzejurgen investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT stehlingflorian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT sutharsansivagurunathan investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT welsnermatthias investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem AT weinreichgerhard investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem |